HK1198591A1 - Oxmif as a diagnostic marker - Google Patents

Oxmif as a diagnostic marker Download PDF

Info

Publication number
HK1198591A1
HK1198591A1 HK14112074.8A HK14112074A HK1198591A1 HK 1198591 A1 HK1198591 A1 HK 1198591A1 HK 14112074 A HK14112074 A HK 14112074A HK 1198591 A1 HK1198591 A1 HK 1198591A1
Authority
HK
Hong Kong
Prior art keywords
oxmif
diagnostic marker
pertains
diagnostic
mif
Prior art date
Application number
HK14112074.8A
Other languages
English (en)
Chinese (zh)
Inventor
邁克爾．蒂勒
迈克尔．蒂勒
倫道夫．
伦道夫．J．克西堡曼
．克西堡曼
德克．弗尔克尔
德克．弗爾克爾
帕特里斯．杜亚尔
帕特里斯．杜亞爾
弗里德里希．斯史夫林格
Original Assignee
Baxalta GmbH
Baxalta Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Incorporated filed Critical Baxalta GmbH
Publication of HK1198591A1 publication Critical patent/HK1198591A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
HK14112074.8A 2011-10-07 2012-10-04 Oxmif as a diagnostic marker HK1198591A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161545042P 2011-10-07 2011-10-07
US61/545,042 2011-10-07
US201261624943P 2012-04-16 2012-04-16
US61/624,943 2012-04-16
US201261668841P 2012-07-06 2012-07-06
US61/668,841 2012-07-06
PCT/EP2012/069598 WO2013050453A1 (en) 2011-10-07 2012-10-04 Oxmif as a diagnostic marker

Publications (1)

Publication Number Publication Date
HK1198591A1 true HK1198591A1 (en) 2015-04-30

Family

ID=46980957

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112074.8A HK1198591A1 (en) 2011-10-07 2012-10-04 Oxmif as a diagnostic marker

Country Status (8)

Country Link
US (1) US9958456B2 (https=)
EP (1) EP2748613B1 (https=)
JP (1) JP2014530360A (https=)
AR (1) AR088244A1 (https=)
AU (1) AU2012320597C1 (https=)
HK (1) HK1198591A1 (https=)
TW (1) TW201321408A (https=)
WO (1) WO2013050453A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9958456B2 (en) 2011-10-07 2018-05-01 Baxalta Incorporated OxMIF as a diagnostic marker
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
KR20150029017A (ko) 2012-07-10 2015-03-17 박스터 헬쓰케어 에스에이 항-mif 면역조직화학
US9536304B2 (en) * 2013-08-30 2017-01-03 Dairy Quality Inc. Determining pathogens based on an image of somatic cells in a fluid sample
EP3052943B1 (en) * 2013-10-04 2019-11-20 Cell Ideas Pty Ltd. Biomarkers for cell therapy
CN106068456A (zh) * 2014-01-03 2016-11-02 百深有限责任公司 抗‑mif免疫组织化学
US10626166B2 (en) 2014-08-22 2020-04-21 Baxalta Incorporated Detection of CHO-MIF contaminations
EP3802595A1 (en) * 2018-06-07 2021-04-14 OncoOne Research & Development GmbH Anti-oxmif/anti-cd3 antibody for cancer treatment
EP4069735A1 (en) * 2019-12-06 2022-10-12 OncoOne Research & Development GmbH Anti-oxmif/anti-cd3 bispecific antibody constructs
JP2024505963A (ja) * 2021-02-03 2024-02-08 オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 抗ｏｘＭＩＦ放射性免疫コンジュゲート

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299814A (en) 1979-05-25 1981-11-10 Monsanto Company Radioimmunoassay of MIF
JPH0672158B2 (ja) 1984-05-24 1994-09-14 チバ−ガイギ− アクチエンゲゼルシヤフト 精製されたヒトマクロファージ遊走阻止因子
US4946674A (en) 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
US4708937A (en) 1984-10-15 1987-11-24 Brigham & Women's Hospital Purified migration inhibitory factor also having colony stimulating factor activity
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ES2052602T3 (es) 1986-10-03 1994-07-16 Ciba Geigy Ag Nuevos peptidos afines a las linfocinas.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990011301A1 (en) 1989-03-17 1990-10-04 Genetics Institute, Inc. Human macrophage migration inhibitory factor
US5785054A (en) 1989-06-06 1998-07-28 Kelly; Patrick D. Genital lubricant with zinc salt, labelled as anti-viral agent
GB8915414D0 (en) 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
EP0457875A4 (en) 1989-11-13 1993-03-03 Xoma Corporation Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5227459A (en) 1990-05-18 1993-07-13 Yale University Synthetic melanin
US5786168A (en) 1990-06-04 1998-07-28 Kirin Beer Kabushiki Kaisha Method for recombinant production of antigen non-specific glycosylation inhibiting factor (GIF)
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US6645493B1 (en) 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US6774227B1 (en) 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
JP4708510B2 (ja) 1993-05-17 2011-06-22 サイトカイン ファーマサイエンシズ，インコーポレーテッド サイトカイン媒介毒性に関係する疾患の治療における遊走阻止因子の抑制
US5559028A (en) 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
EP0770086A4 (en) 1994-05-16 1998-07-15 Human Genome Sciences Inc MACROPHAGE MIGRATION INHIBITING FACTOR-3
US5747023A (en) 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
SI9400363A (en) 1994-09-19 1996-08-31 Mozetic Francky Bojana Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein
AU4365796A (en) 1994-11-16 1996-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor
JPH0977799A (ja) 1995-09-13 1997-03-25 Sapporo Immuno Diagnostic Lab:Kk ヒト−マクロファージ遊走阻止因子（ヒト−ｍｉｆ）に対するモノクローナル抗体および該抗体を産生するハイブリドーマ
WO1997025344A1 (en) 1996-01-03 1997-07-17 The Australian National University Clip analogues and autoimmune disease
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US6420188B1 (en) 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
US5726020A (en) 1996-06-11 1998-03-10 University Of Massachusetts Inhibition of II synthesis
US6297253B1 (en) 1996-10-15 2001-10-02 The Picower Institute For Medical Research Compounds and methods of use to treat infectious diseases
US6326465B1 (en) 1997-02-24 2001-12-04 The Johns Hopkins University Immunomodulatory polypeptides derived from the invariant chain of MHC class II
JP3835827B2 (ja) 1997-05-02 2006-10-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンティッド バイ ザ セクレタリーオブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 悪性細胞に対する、ｏｎｃタンパク質を含む、免疫毒素
CA2205680A1 (en) 1997-05-16 1998-11-16 The University Of Western Ontario Clip immunomodulatory peptide
US6011005A (en) 1997-09-18 2000-01-04 The Picower Institute For Medical Research Prevention of pregnancy miscarriages
AU747767B2 (en) 1997-11-05 2002-05-23 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
EP1156823B1 (en) 1999-02-12 2008-10-29 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
CA2389229A1 (en) 1999-10-29 2001-05-10 The Picower Institute For Medical Research Compounds having mif antagonist activity
US6268151B1 (en) 2000-01-20 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of macrophage migration inhibitory factor expression
WO2001064749A2 (en) * 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
DK1383919T3 (da) 2001-03-29 2010-11-08 Cytokine Pharmasciences Inc Fremgangsmåder og sammensætninger til anvendelse af MHC klasse II-invariant kædepolypeptid som en receptor for makrofag migrationsinhiberede faktor
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
US7205107B2 (en) 2001-12-21 2007-04-17 Cytokine Pharmasciences, Inc. Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease
US20050202010A1 (en) 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
SG153825A1 (en) 2005-12-16 2009-07-29 Ibc Pharmaceuticals Inc Multivalent immunoglobulin-based bioactive assemblies
CN100457895C (zh) 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
US20090220521A1 (en) * 2008-01-04 2009-09-03 Randolf Kerschbaumer Anti MIF Antibodies
EP2079202A1 (en) * 2008-01-08 2009-07-15 NEC Corporation Method for optimizing the triggering of the transmission of buffer status reporting (BSR) information
WO2011090492A1 (en) 2010-01-19 2011-07-28 Immunomedics, Inc. Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
US9958456B2 (en) 2011-10-07 2018-05-01 Baxalta Incorporated OxMIF as a diagnostic marker
WO2013050457A1 (en) 2011-10-07 2013-04-11 Baxter Healthcare S.A. Characterization of cho-mif gene and protein, and use thereof

Also Published As

Publication number Publication date
US20140248638A1 (en) 2014-09-04
JP2014530360A (ja) 2014-11-17
AR088244A1 (es) 2014-05-21
EP2748613A1 (en) 2014-07-02
TW201321408A (zh) 2013-06-01
US9958456B2 (en) 2018-05-01
AU2012320597C1 (en) 2015-10-15
EP2748613B1 (en) 2021-05-05
WO2013050453A4 (en) 2013-06-06
AU2012320597A1 (en) 2013-05-09
AU2012320597B2 (en) 2015-05-21
WO2013050453A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
HK1198591A1 (en) Oxmif as a diagnostic marker
WO2014159822A3 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
WO2011008349A3 (en) Methods of identifying infectious disease and assays for identifying infectious disease
WO2012149299A3 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2014107599A3 (en) Compositions and methods for detecting protease activity in biological systems
CA3290895A1 (en) Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
WO2012129341A3 (en) Disease detection in plants
WO2012078623A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
WO2012054638A3 (en) Nmr systems and methods for the detection of analytes
MA34091B1 (fr) Anticorps anti-cd40
HUE047874T2 (hu) Vér dendritikus sejt antigén 2 elleni antitestek és alkalmazásuk
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
WO2012112315A3 (en) Methods for diagnosis of kawasaki disease
WO2012017323A3 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv
WO2012058292A3 (en) Parathyroid hormone variants and assays related to disease
WO2012041867A3 (en) Combined antigen and dna vaccine for preventing and treating autoimmune diseases
WO2012049225A3 (de) Markersequenzen für systemischer lupus erythematodes und deren verwendung
WO2012092539A3 (en) Antibodies to dll4 and uses thereof
WO2013170057A3 (en) Quantification of lipoproteins
WO2014100602A8 (en) Treatment of egf-receptor dependent pathologies
WO2014169011A3 (en) Methods for treating immune diseases
WO2012042062A3 (de) Markersequenzen für multiple sklerose und deren verwendung
WO2015091902A3 (en) Determination of platelet-mirnas in alzheimer's disease
WO2008120006A3 (en) Diagnostic assay
WO2014049580A3 (en) Assay to monitor autophagy, a method and kit thereof